

PATENT Docket No. 381552001700 Client Ref. MPI2000-282P1R

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 143875931 US

Date of Deposit: September 25, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231.

U. bk -

RECEIVED

OCT 1 1 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

In the application of:

Maria A. GLUCKSMANN

Serial No.:

09/896,522

Filing Date:

June 28, 2001

For:

57658, A NOVEL HUMAN URIDINE

KINASE AND USES THEREOF

Examiner: To Be Assigned

Group Art Unit: 1645

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. Copies of the documents Nos. 2 & 4 are submitted in an electronic form in view of the enormous size of these documents. The Examiner is requested to make these documents of record.

The documents listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

	This In	formation Disclosure Statement is submitted:			
П	With tl	ne application; accordingly, no fee or separate requirements are required.			
\boxtimes		three months of the application filing date or before mailing of a first Office			
		on the merits; accordingly, no fee or separate requirements are required.			
	After r	After receipt of a first Office Action on the merits but before mailing of a final Office			
	Action	or Notice of Allowance.			
		A fee is required. A check in the amount of * is enclosed.			
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached			
		to this submission in duplicate.			
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee			
		is believed to be due.			
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the			
	issue				
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the			
		amount of * is enclosed.			
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal			
		form (PTO/SB/17 is attached to this submission in duplicate.			

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 381552001700. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 25, 2002

Respectfully submitted,

Irina E. Bitva

Registration No. 50,498

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5175 Facsimile: (858) 720-5125

Please type a lus sign (+) inside this box →

FECH CENTER 1600/2900

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ider the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL **FORM**

09/896.522 **Application Number** June 28, 2001 Filing Date Maria A. GLUCKSMANN **First Named Inventor Group Art Unit** 1645 To Be Assigned **Examiner Name**

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

381552001700 Attorney Docket No.

TECH	CENT	ER	160	0/290

\succeq		NO COURTS (shock all that apply)							
		NCLOSURES (check all that apply) Assignment Papers After Allowance Communication to							
	Fee Transmittal Form	(for an Application) Group							
	Fee Attached	Drawing(s) Appeal Communication to Board of Appeals and Interferences							
	Amendment / Reply	Licensing-related Papers Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)							
	After Final	Petition Proprietary Information							
	Affidavits/declarations	Petition to Convert to a Provisional Application Status Letter							
	Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please identify below): Return postcard; Copy of the International Search Report							
		Terminal Disclaimer							
	Express Abandonment Request	Request for Refund							
×	Supplemental Information Disclosure Statement; PTO form 1449; and 11 references (2 are on CD-R)	CD, Number of CD(s)1							
	Certified Copy of Priority Document(s)	Remarks							
	Response to Missing Parts/ Incomplete Application								
	Response to Missing Parts under 37 CFR 1.52 or 1.53								
	ATTORNEY OF ACENT								
<u> </u>		JRE OF APPLICANT, ATTORNEY OR AGENT							
Firm	Irina E. Britva								
or									
Indivi	idual Name								
Signature 4.55									
Date	September 25, 2002								
		THE PARTY OF A CO. MAIL ?							

CERTIFICATE	OF MAIL	ING BY	"FIRST	CLASS	MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 25, 2002.

Irina E/Britva

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Form PTO-1449				L	Docket Number 381552001700 Application Number 09/896,522				
PINFORMATION DISCLOSURE CITATION IN AN APPLICATION				4	Applicant Maria A. GLUCKSMANN				
2 5 2002	: 1	e several sheets if			Filing Date June 28, 20	01	Group Art Unit	1645	
.6					Mailing Date Septembe	R	ECE	IVE	
TRADENA	<u></u>							OCT 1	1 200
			U.S. PA	ΓENT	DOCUMENTS	S	TECH	H CENTER	R 1600
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing I Appro	
			FOREIGN I	PATE	NT DOCUME!	NTS			
Examiner Initials	Ref. No.	Date	Document No.	Country Class		Subclass	Trans YES	lation NO	
	1.	08/1999	WO 99/38972	wo					
	2.	02/2001	EP 1074617A	EP					
	3.	07/2001	WO 01/53312	wo					
	4.	08/2001	WO 01/55367	wo					
Examiner Initials	Ref. No.	Title				2106			
	5.	Ahmed, N.K. et al. (1979) Cancer Research 39(8):3102-3106							
	6.	Connolly, G.P. et al. (1999) Trends in Pharmacological Sciences 20(5):218-225							
	7.	Database EMBL Sequence Library [Online], retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ? -E+[EMBL-ID:AL358781] Database AN. AL358781, XP002202931							
	8.	Database EMBL Sequence Library [Online], retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ? -E+[EMBL-ID:AK022317] Database AN. AK022317, XP002202932							
	9.	Database WPI, Section Ch, Week 200144, Derwent Publications Ltd., London, GB Class B04, AN 2001-409529, XP002202933							
	10.	Van Rompay, A. et al. (2001) Moleculat Pharmacology 59(5):1181-1186							
	11.	(1977) Biochemical Pharmacology 26:64-66 -							
EXAMI	NER:				DATE CON	NSIDERED:	<u> </u>		